STANDARD BIOTOOLS INC. (LAB)

1.33 0.04 (3.1%)

As of 2025-10-16 18:38:15 EST

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Traded asNasdaq: LAB
ISINUS34385P1084
CIK0001162194
LEI—
EIN770513190
Sector—
IndustryLaboratory Analytical Instruments
CEOMichael Egholm
Employees615
Fiscal Year End1231
Address2 TOWER PLACE, SOUTH SAN FRANCISCO, CA, 94080
Phone6502666000
Websitehttps://standardbio.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
LABSTANDARD BIOTOOLS INC.2025-10-16 18:38:151.330.043.1
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
LAB0001162194STANDARD BIOTOOLS INC.US34385P1084—770513190Nasdaq3826Laboratory Analytical Instruments1231DE2 TOWER PLACESOUTH SAN FRANCISCOCA94080UNITED STATESUS65026660002 TOWER PLACE, SOUTH SAN FRANCISCO, CA, 940802 TOWER PLACE, SOUTH SAN FRANCISCO, CA, 94080FLUIDIGM CORP—1999Michael Egholm615https://standardbio.com433,100,000400,273,000381,995,102Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.2025-10-10 21:46:16
This is a preview of the latest data. Subscribe to access the full data.
LAB Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
LAB Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024433,100,000300,400,000226.3753378,986,362125,6760.0332
2023132,700,0006,852,3175.4449378,860,686299,796,758379.1827
2022125,847,683-337,905,644-72.863279,063,9281,865,3512.4163
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Colin MccrackenChief Commercial Officer2021387,8660943,584054,9031,386,353
Bradley KregerSenior Vice President2021344,7600546,58603,000894,346
Stephen ChristopherCEO, President2021595,00002,677,147039,5153,311,663
Vikram JogChief Financial Officer2021384,3000718,36403,0001,105,664
Nicholas KhadderSecretary, General Counsel, Senior Vice President2021352,6830564,87603,000920,559
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024818
2023928
2022523
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue174,432,000106,340,00097,948,000
Cost Of Revenue90,170,00055,890,00052,555,000
Gross Profit84,262,00050,450,000—
Research And Development Expenses62,411,00025,948,00038,498,000
General And Administrative Expenses156,608,00087,541,000114,758,000
Operating Expenses259,498,000127,050,000214,153,000
Operating Income-175,236,000-76,600,000-116,205,000
Net Income-138,885,000-74,656,000-190,098,000
Earnings Per Share Basic-0.52-0.94-2.43
Earnings Per Share Diluted-0.52-0.94-2.43
Weighted Average Shares Outstanding Basic353,245,00079,160,00078,305,000
Weighted Average Shares Outstanding Diluted353,245,00079,160,00078,305,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents166,728,00051,704,00081,309,000
Marketable Securities Current126,146,00063,191,00084,475,000
Accounts Receivable33,608,00019,660,00017,280,000
Inventories40,737,00020,533,00021,473,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current375,880,000158,215,000208,815,000
Marketable Securities Non Current———
Property Plant And Equipment42,556,00024,187,00025,652,000
Other Assets Non Current6,301,0002,285,0003,109,000
Total Assets Non Current71,384,00054,850,000181,495,000
Total Assets612,344,000323,067,000390,310,000
Accounts Payable12,282,0009,236,0007,914,000
Deferred Revenue13,118,00011,607,00010,792,000
Short Term Debt05,000,0000
Other Liabilities Current30,739,0009,152,0006,175,000
Total Liabilities Current65,894,000109,327,00043,443,000
Long Term Debt299,00063,513,000600,000
Other Liabilities Non Current6,962,0001,065,000961,000
Total Liabilities Non Current74,728,00050,538,000117,081,000
Total Liabilities140,622,000159,865,000160,524,000
Common Stock396,00083,00080,000
Retained Earnings-1,185,651,000-1,000,752,000-926,096,000
Accumulated Other Comprehensive Income1,225,000-2,221,000-1,896,000
Total Shareholders Equity471,722,000-148,051,000-81,467,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization12,300,00012,673,0006,223,000
Share Based Compensation Expense31,732,00013,123,00014,880,000
Other Non Cash Income Expense———
Change In Accounts Receivable-8,967,0002,991,000-1,063,000
Change In Inventories9,879,0004,914,0008,470,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-12,975,0001,618,000-2,776,000
Change In Other Liabilities-4,184,0003,212,000-5,978,000
Cash From Operating Activities-143,454,000-43,287,000-89,370,000
Purchases Of Marketable Securities256,119,00094,896,000137,302,000
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment8,355,0002,831,0003,825,000
Acquisition Of Business1,385,000——
Other Investing Activities———
Cash From Investing Activities363,174,00020,237,000-88,127,000
Tax Withholding For Share Based Compensation459,000139,000211,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock40,490,0005,414,000563,000
Issuance Of Long Term Debt——0
Repayment Of Long Term Debt——0
Other Financing Activities—827,000917,000
Cash From Financing Activities-102,616,000-6,809,000230,758,000
Change In Cash116,319,000-29,825,00052,857,000
Cash At End Of Period166,728,00051,704,00081,309,000
Income Taxes Paid607,000801,000309,000
Interest Paid3,088,0003,819,0003,493,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-0.52-0.94-2.43
Price To Earnings Ratio-3.3654-2.3511-0.4815
Earnings Growth Rate-44.6809-61.3169211.5385
Price Earnings To Growth Ratio0.07530.0383-0.0023
Book Value Per Share1.33542.06172.9345
Price To Book Ratio1.31051.07190.3987
Ebitda-125,978,000-56,615,000-179,235,000
Enterprise Value451,749,750191,752,60010,907,850
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.0006-0.4628-0.0074
Capital Expenditures30,669,00011,208,0003,841,000
Free Cash Flow-174,123,000-54,495,000-93,211,000
Return On Equity-0.29440.50432.3334
One Year Beta1.63031.52981.582
Three Year Beta1.57471.48191.3215
Five Year Beta1.35431.31541.2559
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Casdin Partners Master Fund, L.P.Director, 10% owner2025-09-09100,000A60,875,000
Casdin Partners Master Fund, L.P.Director, 10% owner2025-09-04250,000A60,775,000
Casdin Partners Master Fund, L.P.Director, 10% owner2025-09-03250,000A60,525,000
Casdin Partners Master Fund, L.P.Director, 10% owner2025-08-26125,000A60,275,000
Casdin Partners Master Fund, L.P.Director, 10% owner2025-08-25200,000A60,150,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Blue Trust, Inc.2025-09-3026201.3
CWM, LLC2025-09-3040,00030,5521.3092
Farther Finance Advisors, LLC2025-09-30751.4
DLK Investment Management, LLC2025-09-3014,79411,3801.3
VOYA INVESTMENT MANAGEMENT LLC2025-09-3075,92358,4021.3
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap FundCFSLX52,12865,681.280.0137
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap Select FundCFSSX295,772372,672.720.0259
Global X Funds2025-07-31Global X Russell 2000 ETFRSSL151,638201,678.540.0153
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Total Market Index FundFZROX135,086179,664.380.0006
FIDELITY CONCORD STREET TRUST2025-07-31Fidelity ZERO Extended Market Index FundFZIPX89,840119,487.20.0065
This is a preview of the latest data. Subscribe to access the full data.